The hepatitis B virus establishes its persistence through a peculiar molecular intermediate known as covalently closed circular DNA, or cccDNA. After the virus enters a hepatocyte, its partially double-stranded circular genome travels to the nucleus, where host repair enzymes convert it into a fully double-stranded, covalently closed circle. This minichromosome behaves remarkably like a cellular chromosome: it is wrapped in histone proteins, carries epigenetic marks, and serves as the template for all of the viral RNA transcripts that drive the production of new virions and, critically, of hepatitis B surface antigen, the viral protein that accumulates to enormous levels in the blood of chronically infected patients and is thought to exhaust and dysregulate antiviral immune responses. Because cccDNA is extraordinarily stable and can persist in dividing and non-dividing hepatocytes alike, clearing it has been the elusive goal of hepatitis B research for decades.

Existing treatments manage the consequences of cccDNA activity rather than the reservoir itself. Nucleoside and nucleotide analogues, such as tenofovir and entecavir, potently inhibit the viral polymerase and prevent new rounds of replication, but they leave cccDNA untouched, which is why discontinuation almost universally leads to viral rebound. Pegylated interferon-alpha can produce functional control in a minority of patients, likely through a combination of direct antiviral and immunomodulatory effects, but its tolerability is poor and its cure rates remain low. The result is that most patients face lifelong daily therapy, and the dream of a finite treatment course that leaves the liver free of active viral transcription has remained out of reach. Epigenetic silencing offers a conceptual alternative: if the viral minichromosome can be rendered permanently or durably transcriptionally silent, the virus may be functionally inactivated even though its DNA physically remains.

The investigational therapy described in the new study is built on this premise. It is designed as an epigenetic silencer, a construct that targets the hepatitis B viral DNA and recruits repressive chromatin-modifying machinery to the viral genome, thereby converting the active cccDNA minichromosome into a heterochromatic, transcriptionally inert state. In practical terms, the therapy aims to deposit repressive histone marks and promote DNA methylation patterns at the viral regulatory elements that normally drive transcription of all the viral RNAs, including the pregenomic RNA that seeds new replication and the abundant subgeniral RNAs that encode surface and core proteins. By shutting down transcription at its source, the approach addresses both the production of infectious virus and the antigenemia that blunts immune recovery.

The engineering challenge at the heart of such a therapy is specificity. The human liver contains roughly two hundred billion hepatocytes, and the silencing machinery must find the small fraction of cells harboring transcriptionally active cccDNA while leaving the host genome and its epigenetic landscape untouched. The reported system couples a DNA-binding module that recognizes sequences within the hepatitis B genome to effector domains capable of recruiting repressive complexes. Because the viral regulatory region, including the core promoter and enhancer elements, contains sequence features that are conserved across hepatitis B genotypes but absent from the human genome in the same configuration, the design exploits a natural sequence boundary between pathogen and host. Delivery to hepatocytes is achieved with a liver-directed formulation intended to concentrate the payload in the organ where more than ninety percent of viral replication occurs.

Epigenetic silencing of viral genomes is not an entirely new idea, but translating it into a viable therapy has required overcoming several biological realities. The first is that cccDNA is not a static target: it exists in variable copy numbers per cell, ranges from fully active to partially silenced states even within a single liver, and can be replenished from integrated viral DNA in some patients. The second is reversibility. Epigenetic marks are, by definition, modifiable, and a silenced minichromosome could in principle be reactivated if repressive marks decay or if the cell encounters inflammatory or proliferative signals that remodel chromatin. The investigators therefore designed the therapy not merely to deposit transient repressive marks but to establish a self-reinforcing silenced state, in which repressive chromatin at the viral promoter recruits further repressive machinery, creating a memory of inactivation that persists across time and, in dividing cells, across cell generations.

The functional consequences of such silencing would extend beyond simply lowering viral load. Hepatitis B surface antigen is now understood to be a principal driver of immune dysfunction in chronic infection, with circulating subviral particles reaching concentrations of micrograms per milliliter and contributing to the exhaustion of natural killer cells, T cells, and B cells that would otherwise clear infected hepatocytes. A therapy that transcriptionally inactivates cccDNA would be expected to produce a steep and sustained decline in surface antigen, removing this immunosuppressive burden and creating the conditions under which the patient’s own immune system can recognize and eliminate residual infected cells. In this sense, epigenetic silencing is best understood not as a standalone cure but as the keystone of a combination strategy, in which silencing of the reservoir is followed or accompanied by therapeutic vaccination, immune checkpoint modulation, or other immunorestorative interventions that consolidate the gain.

Safety considerations loom large for any therapy that deliberately manipulates chromatin. Broadly acting epigenetic drugs, such as the histone deacetylase inhibitors developed in oncology, carry systemic toxicity profiles that make them unattractive for chronic liver disease. The investigational silencer is therefore designed to act locally and selectively, with its repressive activity confined to the viral sequences it is targeted to. Another concern is the fate of integrated hepatitis B DNA, which in many chronic infections is scrambled into host chromosomes and cannot be circularized or fully silenced by the same mechanism; integrated DNA is a known source of surface antigen production and, in some contexts, of insertional mutagenesis that contributes to hepatocellular carcinoma. The therapy’s developers and independent commentators alike emphasize that silencing cccDNA addresses the replicative reservoir but does not by itself excise integrated sequences, underscoring that long-term monitoring for surface antigen rebound and for liver cancer risk will remain necessary even in successfully treated patients.

The publication arrives at a moment of unusual momentum in hepatitis B cure research. Dozens of candidates are advancing through clinical pipelines, including entry inhibitors, capsid assembly modulators, RNA interference therapeutics that degrade viral transcripts, surface antigen secretion inhibitors, and therapeutic vaccines. RNA interference drugs in particular have demonstrated that reducing viral antigen is feasible and well tolerated, and several have advanced to late-stage trials, though rebound after discontinuation has highlighted the persistence of the cccDNA reservoir that RNA-based approaches cannot touch. An epigenetic silencer occupies a distinctive position in this landscape because it acts on the reservoir itself, at the level of the minichromosome, rather than on the RNA or protein products that flow from it. If its silenced state proves durable, it could provide the reservoir control that RNA interference and direct-acting antivirals lack, while complementing the immune-directed agents needed to finish the job.

Much work remains before such a therapy could reach patients. The path from proof of concept in laboratory and animal models of hepatitis B infection to demonstrated safety and efficacy in humans is long, and epigenetic therapies will face scrutiny from regulators accustomed to evaluating small molecules and antibodies. Questions about the completeness of silencing across the enormous heterogeneity of cccDNA populations, the behavior of the therapy in patients with high viral loads and advanced fibrosis, the potential for rare escape variants in the targeted viral sequences, and the reversibility of the silenced state over years rather than weeks will all need rigorous answers. Nevertheless, the development of an investigational therapy designed to transcriptionally inactivate viral DNA marks a conceptual milestone: it treats the hepatitis B minichromosome not as an untouchable fixture of chronic infection but as an epigenetic state that can be rewritten. For the hundreds of millions of people living with chronic hepatitis B, the prospect of a finite course of treatment that leaves the virus silent, the immune system restored, and the liver protected represents a goal that has never been closer to serious experimental pursuit.

Subject of Research: Development of an investigational epigenetic silencer therapy that transcriptionally inactivates hepatitis B viral DNA in chronic hepatitis B

Article Title: Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B

Article References: Anglero-Rodriguez, Y., Xiong, Q., Cappelluti, M. A., Voytek, S. B., Acosta, G., Choo-Wing, R., Hoffman, L., Khadka, A., Medina, J. A., Mugambwa, C., Pantano, C., Harel, S., DiPiazza, A., Abraham, S., Hildebrand, E. M., Ramirez, R. N., Zhai, A., Guo, X., Abubucker, S., … Marlowe, J. L. (2026). Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01802-8

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01802-8

Keywords: chronic hepatitis B, hepatitis B virus, cccDNA, epigenetic silencing, viral DNA, hepatitis B surface antigen, antiviral therapy, chromatin modification, functional cure, liver disease, RNA interference, transcriptional repression

Yet the numbers remain sobering. According to the review, even with the best currently available regimens, the functional cure rate among patients with chronic hepatitis B stays below 30 percent, and in many treatment settings it is far lower. Nucleos(t)ide analogues such as entecavir and tenofovir suppress viral replication with remarkable potency and an excellent safety profile, but they act on the reverse transcriptase step of the hepatitis B virus life cycle and leave the intracellular reservoirs of viral genetic material untouched. Pegylated interferon-alpha, the other pillar of standard therapy, can reinvigorate antiviral immune responses in a subset of patients, but response rates are limited and tolerability issues frequently force discontinuation. The result is a therapeutic plateau: viral suppression is easy to achieve, but genuine immune-mediated control of the infection remains the exception rather than the rule.

At the heart of this plateau, the authors identify the persistence of covalently closed circular DNA, or cccDNA, as the central virological obstacle. cccDNA is the circular, episodic form of the hepatitis B virus genome that resides in the nucleus of infected hepatocytes and serves as the transcriptional template for all viral RNAs, including the pregenomic RNA from which new viral particles are assembled. Because cccDNA is stable, long-lived and present in minute quantities per cell, it evades both the cytoplasmic degradation pathways triggered by nucleos(t)ide analogues and the surveillance of the immune system, which struggles to recognize infected hepatocytes that produce little or no viral antigen. Clearing cccDNA from the liver would require either eliminating every infected hepatocyte or inducing selective degradation of the minichromosome itself, and neither approach is currently achievable with acceptable safety in the overwhelming majority of patients.

Compounding the cccDNA problem is a second form of viral persistence that the review highlights in detail: the integration of hepatitis B virus DNA into the genome of the host hepatocyte. Integration occurs frequently during the chronic phase of infection, driven by the_error-prone nature of viral replication and the continual turnover of infected cells. Integrated viral sequences are typically rearranged and replication-defective, but they can act as persistent factories for hepatitis B surface antigen, sustaining high circulating levels of HBsAg even when cccDNA transcription has been effectively silenced. This has two major consequences. First, integrated DNA means that surface antigen loss cannot automatically be equated with the elimination of the viral reservoir, complicating the interpretation of treatment endpoints. Second, chromosomal integration is a recognized mutagenic event, and insertional disruption of host genes such as TERT has been implicated in the development of hepatocellular carcinoma, linking viral persistence directly to the most feared clinical outcome of chronic infection.

The review then turns to the immunological face of the problem, describing how prolonged exposure to elevated levels of viral antigens — above all hepatitis B surface antigen and hepatitis B e antigen — induces a state of immune tolerance that is sculpted from the very earliest stages of infection. In patients infected at birth or in early childhood, the developing immune system encounters enormous quantities of circulating antigen during the critical windows in which tolerance mechanisms are established. High antigen loads drive the deletion or functional silencing of HBV-specific T cells, promote the differentiation of regulatory T cells and exhaust antigen-presenting dendritic cells, so that by the time chronicity is established the immune system has been trained, in effect, to ignore the virus. Maternal antigen passage and the unique tolerogenic environment of the liver, which is continuously exposed to gut-derived material and normally biased toward immune non-responsiveness, reinforce this state and help explain why infection acquired early in life so rarely resolves spontaneously.

Even in patients whose T cells do persist, the review documents a landscape of immune exhaustion and dysfunction operating at multiple regulatory levels. HBV-specific CD8 T cells in chronic hepatitis B display the classic molecular signature of exhaustion: sustained expression of inhibitory receptors such as PD-1, CTLA-4, TIM-3 and LAG-3, shortened telomeres, impaired cytotoxic function and a shift toward a terminally differentiated, senescent phenotype. CD4 helper function is similarly compromised, weakening the support that CD8 cells require for sustained antiviral activity. Beyond the T cell compartment, natural killer cell function is dysregulated, B cell responses are blunted with defective production of neutralizing anti-HBs antibodies, and the intrahepatic cytokine milieu — enriched in suppressive mediators such as interleukin-10 and indoleamine 2,3-dioxygenase — actively restrains inflammatory responses. Exhausted T cells, the authors emphasize, are not simply passive casualties; they represent a partially reversible differentiation state, which is precisely why they have become the focal point of new immunotherapeutic strategies.

It is against this mechanistic backdrop that the review surveys the emerging arsenal of immunotherapy. Therapeutic vaccines aim to present HBV antigens in an immunogenic context that can break tolerance and prime new antiviral T cell responses. Checkpoint inhibitors, most notably antibodies directed against PD-1 or PD-L1, seek to reverse the exhausted state of HBV-specific T cells, an approach supported by incidental observations of HBsAg decline in cancer patients treated with such agents. Agonists of pattern-recognition receptors, including Toll-like receptor 7 and 8 agonists, are designed to reawaken innate antiviral defenses and restore interferon production within the liver. Additional strategies under investigation include engineered T cell technologies, cytokine modulation, and combinations that pair direct-acting antivirals with immune interventions to first reduce antigen load and then rebuild antiviral immunity. The authors stress, however, that no single agent has yet demonstrated the capacity to induce functional cure reliably, and that the field’s most promising direction lies in rational combination: reducing the antigenic burden, releasing the brakes on T cell function, and providing the innate cytokine signals needed to coordinate a durable multi-layered response.

The review also underscores why the liver’s unique immunobiology makes this task so difficult. The hepatic environment is constitutively tolerogenic, populated by liver sinusoidal endothelial cells, Kupffer cells and stellate cells that favor the induction of regulatory rather than effector T cell responses. Any curative strategy must therefore overcome not only the viral reservoirs and the exhaustion of the adaptive immune system, but also an organ-specific architecture that has evolved to suppress inflammation. Biomarker development is identified as an equally pressing need: quantitative HBsAg levels, hepatitis B RNA signatures and emerging measures of immune restoration are all being explored as tools to identify which patients are most likely to benefit from which combination, and to shorten the lengthy trials that current endpoints demand.

By synthesizing virological persistence mechanisms, the layered failure of antiviral immunity and the emerging immunotherapeutic toolkit into a single framework, Lin, Yu and Sun aim to provide both a theoretical foundation and practical critical perspective for the clinical translation of functional cure strategies. Their central message is one of mechanistic realism: the obstacles to curing chronic hepatitis B functionally are not a single barrier but an interlocking system of viral reservoirs, integrated DNA, antigen-driven tolerance and multi-level immune exhaustion. Understanding how these pieces reinforce one another — and designing combinations that dismantle them in the correct sequence — is, the authors conclude, the surest path toward turning a goal achieved by fewer than a third of patients today into a routine clinical outcome tomorrow.

Subject of Research: Immunological mechanisms and barriers to achieving a functional cure for chronic hepatitis B

Article Title: The core obstacles and immunological mechanisms in the study of functional cure for Chronic Hepatitis B

Article References: Lin, L., Yu, D., & Sun, S. (2026). The core obstacles and immunological mechanisms in the study of functional cure for Chronic Hepatitis B. Virology Journal. https://doi.org/10.1186/s12985-026-03310-2

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03310-2

Keywords: chronic hepatitis B, functional cure, HBV, cccDNA, HBsAg loss, immune exhaustion, viral integration, immunotherapy, T cell dysfunction, immune tolerance, liver disease, antiviral therapy

Hepatitis B virus (HBV) remains one of the world’s most consequential pathogens. An estimated 254 million people were living with chronic HBV infection in 2022, and roughly 1.1 million deaths were attributed to the virus that year. China carries the heaviest national burden, with approximately 75 million infected individuals. Chronic infection drives cirrhosis and hepatocellular carcinoma (HCC), but accumulating evidence also links chronic HBV to elevated risks of digestive system malignancies, kidney disease, and mortality from cardiovascular and cerebrovascular conditions compared with the general population. Against this backdrop, the World Health Organization has endorsed a global strategy to eliminate viral hepatitis by 2030, emphasizing both the prevention of new infections and the expansion of diagnosis and treatment to reduce mortality among those already infected.

Loss of HBsAg is the central therapeutic goal in chronic hepatitis B and underpins the treatment endpoint known as functional cure. Spontaneous HBsAg seroclearance also occurs during the natural course of infection, though infrequently — roughly 1 percent of patients per year. Prior research has consistently shown that patients who clear HBsAg experience substantially lower rates of cirrhosis and HCC. What remained uncertain, however, was whether seroclearance is also associated with overall survival and, in particular, with extrahepatic mortality from cancers and cardiovascular disease — a question of growing importance as the population of people living with chronic hepatitis B ages and accumulates comorbidities.

To address this gap, investigators drew on the Chronic Hepatitis B Infection and Liver Disease (HEPCARE) study, a multicenter, prospective, community-based cohort in Jiangsu Province. Participants were recruited through serological surveys conducted between September 2009 and November 2010 and were required to be HBsAg-positive, hepatitis C antibody-negative, and free of cirrhosis and liver cancer at enrollment. Because HBV DNA measurements began at the 2012 follow-up, the analysis defined 2012 as baseline and followed participants through December 2023, with assessments in 2012, 2013, 2014, 2016, 2018, 2020, and 2023. After exclusions, 6551 participants entered the analytical pool, and after propensity score matching on age, sex, region, and baseline antiviral treatment status, the final matched cohort comprised 1029 individuals who achieved sustained HBsAg seroclearance with HBV DNA below 100 IU/mL and 2931 who remained persistently HBsAg-positive.

A key methodological strength of the study lies in its handling of time. HBsAg seroclearance is a time-dependent event that occurs during follow-up, and conventional analyses that treat it as a fixed baseline characteristic are vulnerable to immortal time bias, which can distort survival estimates. By conducting regular interval surveillance and using time-dependent Cox regression, the researchers could allocate person-time accurately according to each participant’s changing serovirological status. The exposure itself was stringently defined: seroclearance required HBsAg negativity together with HBV DNA below the quantification limit of 100 IU/mL, confirmed at two or more consecutive follow-up visits, with participants whose profiles suggested occult hepatitis B infection excluded to avoid misclassification.

The results were striking across multiple outcome domains. Over a median follow-up of roughly 11 years, participants who achieved sustained seroclearance had significantly lower incidence rates of cirrhosis (2.02 versus 3.97 per 1000 person-years) and HCC (2.97 versus 4.97 per 1000 person-years). In fully adjusted time-dependent Cox models, seroclearance was associated with a 55 percent lower hazard of cirrhosis (adjusted hazard ratio 0.45) and a 48 percent lower hazard of HCC (adjusted hazard ratio 0.52). Mortality told a similar story: 64 deaths occurred in the seroclearance group compared with 405 in the persistent infection group, corresponding to incidence rates of 7.55 and 12.17 per 1000 person-years, and seroclearance was associated with a 53 percent lower hazard of all-cause mortality (adjusted hazard ratio 0.47).

Perhaps the most novel findings concerned cause-specific mortality. Among the 469 deaths in the matched population, 146 were attributed to extrahepatic cancers, 117 to cardiovascular disease, and 112 to liver-related causes. Sustained seroclearance was associated with lower hazards of liver-related mortality (adjusted hazard ratio 0.46), extrahepatic cancer-related mortality (0.51), and cardiovascular mortality (0.56), with the strongest association observed for digestive system cancer-related mortality. When competing risks were formally accounted for using Fine–Gray subdistribution hazard models, these associations persisted for cirrhosis, HCC, liver-related mortality, and extrahepatic cancer-related mortality, and model-standardized cumulative incidences at 10 years were consistently lower in the seroclearance state for all major endpoints examined.

The investigators then asked whether HBsAg loss carries prognostic information beyond viral DNA suppression alone — a clinically important question, since suppressing HBV DNA below 100 IU/mL is a conventional treatment goal. In an analysis treating serovirological status as a three-state time-varying variable, the HBsAg-negative state with very low HBV DNA was associated with lower hazards of cirrhosis, HCC, all-cause mortality, extrahepatic cancer mortality, and cardiovascular mortality compared with the HBsAg-positive state at similarly low viral loads. Conversely, isolated HBV DNA suppression without seroclearance was not associated with lower extrahepatic mortality. Additional weighting analyses incorporating baseline HBV DNA attenuated the HCC estimate somewhat, suggesting that part of that association depends on differences in baseline viral burden, but the associations with all-cause and extrahepatic cancer mortality remained statistically significant.

To translate the associations into population-level terms, the team estimated population attributable fractions and restricted mean survival time. Persistent infection was associated with attributable fractions of approximately 48 percent for cirrhosis, 47 percent for liver-related mortality, 42 percent for all-cause mortality, 41 percent for HCC, 40 percent for extrahepatic cancer mortality, and 35 percent for cardiovascular mortality. Using age as the time scale, restricted mean survival time was estimated at 83.21 years in the seroclearance state versus 78.04 years in the persistent infection state — a 5.17-year difference within the observed age range, with the survival advantage widening notably after age 60. Sex-stratified analyses suggested that these inverse associations were generally stronger in men, with statistically significant interactions for all-cause and liver-related mortality, echoing prior evidence that men with chronic hepatitis B tend to experience less favorable long-term outcomes than women.

The authors caution that most seroclearance events in the cohort occurred spontaneously rather than through antiviral therapy, so the findings primarily reflect the prognosis associated with spontaneous HBsAg loss, which may partly reflect a favorable underlying viral-host profile and overall health status. Residual confounding from unmeasured factors such as socioeconomic status and healthcare utilization cannot be excluded, the assay’s quantification limit of 100 IU/mL may have classified some low-level viremia as undetectable, and the single-province, community-based design warrants validation in other populations, including cohorts enriched for treatment-induced functional cure. Biologically, the authors propose that persistent viral antigen exposure and chronic immune activation may impair tumor immune surveillance and promote systemic inflammation, whereas HBsAg clearance accompanies a marked reduction in antigen burden and partial restoration of HBV-specific immune responses — hypothesis-generating mechanisms that require further study. Nevertheless, the consistency of the associations across competing-risk models, three-state analyses, and extensive sensitivity analyses, combined with the substantial attributable burden and survival differences, positions sustained HBsAg seroclearance with very low HBV DNA as an informative long-term prognostic marker in chronic hepatitis B, and underscores the potential population health value of broader attainment of this serovirological state.

Subject of Research: HBsAg seroclearance and long-term hepatic and extrahepatic mortality risks in chronic hepatitis B

Article Title: HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study

Article References: Zhang, Y., Yao, W., Jiang, J., Qian, J., Chen, X., Jiang, Q., Yan, Y., Wang, S., Bai, H., He, C., Zhu, L., Jiang, T., Hu, Z., Shen, H., Zhai, X., & Song, C. (2026). HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study. The Lancet Regional Health – Western Pacific, 74, Article 101983. https://doi.org/10.1016/j.lanwpc.2026.101983

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101983

Keywords: hepatitis B, HBsAg seroclearance, functional cure, hepatocellular carcinoma, cirrhosis, all-cause mortality, extrahepatic cancer, cardiovascular mortality, HBV DNA, prospective cohort, population attributable fraction, chronic hepatitis B

The central obstacle to a cure is the remarkable persistence architecture of the hepatitis B virus. After the virus enters hepatocytes through the NTCP receptor, its relaxed circular DNA genome is repaired by host factors into covalently closed circular DNA, or cccDNA, a stable episomal minichromosome that persists in the nucleus and serves as the transcriptional template for all viral RNAs and proteins. In parallel, fragments of viral DNA integrate at random sites into the host genome as integrated DNA, or intDNA, which does not produce new virus but continuously secretes surface antigen and, in some cases, the oncogenic HBx protein, fueling immune tolerance and carcinogenesis. Current interferon-alpha and nucleos(t)ide analog therapies leave both reservoirs untouched, so viral rebound is common once treatment stops, and long-term nucleos(t)ide therapy carries risks such as nephrotoxicity.

The Groningen team frames the therapeutic landscape around two epigenetic strategies. The first, broad-acting epidrugs, globally modulate histone- and DNA-modifying enzymes; nine such agents are already FDA-approved in oncology. The second, epigenetic editing, fuses effector enzymes to programmable DNA-binding domains — zinc-finger proteins, transcription activator-like effectors, or deactivated CRISPR-Cas9 — to write repressive marks at specific viral loci. Because HBV gene activity on cccDNA is governed by histone acetylation and methylation, with HBx recruiting p300 to boost H3 and H4 acetylation while SETDB1-mediated H3K9me3 and PRMT1-mediated H4R3 methylation repress transcription, the viral minichromosome is an unusually tractable epigenetic target.

Among epidrugs, sirtuin 2 inhibitors have produced the most compelling results. The SIRT2 inhibitor AGK2 reduced HBV DNA, RNA, HBsAg and HBeAg by 15 to 30 percent in vitro and in HBV-transgenic mice without hepatotoxicity, and recent work showed the drug acts by recruiting repressive histone lysine methyltransferases to cccDNA, enriching H4K20me1, H3K27me3 and H3K9me3 while reducing RNA polymerase II occupancy. A more specific allosteric inhibitor, FLS-359, blocked the conversion of rcDNA into cccDNA entirely in primary human hepatocytes when given before infection, cutting cccDNA formation by more than half — though it was ineffective after infection was established, positioning it as a preventive rather than curative agent. Meanwhile, the DNA methyltransferase inhibitor 5-azacytidine reactivated interferon-stimulated genes and sensitized otherwise unresponsive cells to interferon-alpha, but it also raised NTCP expression and HBsAg levels, highlighting the double-edged nature of globally acting agents.

That lack of locus specificity is precisely what epigenetic editing is designed to fix, and the review catalogs five preclinical editing studies organized around two approaches. Indirect editing directs a Krüppel-associated box, or KRAB, repressor domain to key HBV regulatory elements; KRAB acts as a scaffold recruiting histone deacetylases, lysine methyltransferases and heterochromatin proteins to shut down transcription. Direct editing instead guides DNA methyltransferases such as DNMT3a or the bacterial M.SssI enzyme to CpG islands overlapping viral promoters, writing de novo methylation that can be mitotically inherited. Both routes reduced HBV RNA, DNA and antigens from cccDNA and, in some contexts, from intDNA, with far better specificity than epidrugs.

The zinc-finger platform, the most rigorously studied to date, illustrates both the promise and the limits. Zhao and colleagues built a six-finger ZFP-KRAB artificial transcription factor targeting the X gene enhancer that cut HBx RNA by roughly 60 percent in Hep3B cells, a line carrying integrated viral DNA. Luo and colleagues achieved the most durable result, with HBV DNA falling to about one-third of control levels in transgenic mice by day seven and remaining significantly lower at day 28, although HBsAg was unchanged. The direct approach by Xirong and colleagues, fusing DNMT3a to a ZFP targeting the X promoter CpG island, lowered HBsAg by 58 percent in mice and 90 percent in cells, with confirmed methylation at seven CpG sites — but the effect reversed by day 20, likely through passive or TET-mediated demethylation. A single TALE-based study by Bloom and colleagues delivered the fastest repression, cutting HBsAg and HBV RNA by 80 percent in Huh7 cells within 48 hours and by 80 to 95 percent in mice within five days, though attribution to KRAB was complicated by the absence of a TALE-only control.

The dCas9 platform, which replaces costly protein engineering with inexpensive single-guide RNAs, is now moving fastest toward patients. The only peer-reviewed dCas9 data for HBV come from a doctoral thesis by Rendón, who fused M.SssI to dCas9 and targeted the conserved CpG islands adjacent to the C and S gene promoters, achieving 2 to 15 percent increases in methylation that downregulated C and S gene transcription but faded within 48 hours. Nevertheless, two clinical trials of dCas9 epigenetic editing for hepatitis B are already underway — NCT06745973 and NCT06671093 — and parallel successes silencing HIV provirus with dCas9-KRAB, plus the demonstration that combined KRAB and DNA methyltransferase editors such as CRISPRoff produce durable, heritable silencing, provide strong proof of concept. Notably, dCas9 editing avoids the genotoxicity risk that shadows nuclease-based CRISPR-Cas9 approaches, whose guide RNAs can partially match human genomic sequences and whose double-strand breaks at the many, variable intDNA loci raise off-target mutagenesis concerns.

Industry has now taken up the challenge with three programs. Tune Therapeutics’ Tune-401, a liver-targeting lipid nanoparticle carrying a guide RNA to CGI2 and mRNA encoding a dCas9 fused to a methyltransferase and an undisclosed repressor, reported 99.99 percent repression of cccDNA-derived HBV RNA in primary human hepatocytes, strong repression of RNA and HBsAg from intDNA in Hep3B cells, epigenetic marks persisting through 275 rounds of cell division over 550 days, minimal off-target effects by RNA-seq, and a favorable safety profile in non-human primates — though these results have not yet been peer reviewed. A Phase 1b trial is recruiting in Hong Kong, Moldova and New Zealand. EpiGENIC’s Epi-003, a similar LNP platform, has entered a Phase 1 trial in China, and nChroma Bio’s CRMA-1001 has shown greater than 99 percent HBsAg reduction sustained for six months in preclinical models. A related Omega Therapeutics trial using LNP-delivered ZFP editors in liver cancer further validates liver-directed epigenetic delivery.

Significant hurdles remain before any of this translates into a functional cure. HBV genomes differ by more than 8 percent at the nucleotide level across genotypes, and the error-prone reverse transcriptase plus the chaotic nature of integration create sequence variability that could blunt editing efficacy, demanding bioinformatic surveillance and possibly personalized designs. Heterochromatin spreading from KRAB editors could silence neighboring host genes at unpredictable intDNA sites, while complete silencing of all antigen sources raises the paradox that eliminating HBsAg might allow exhausted immune cells to miss residual infection, arguing for integration with immune-reactivation strategies. Model limitations compound the problem: primary human hepatocytes rarely form intDNA, Hep3B lacks infection dynamics, and the field needs 3D organoid and humanized mouse systems that capture both reservoirs. Cost and equity loom as well, since most patients live in Southeast Asia and Sub-Saharan Africa while comparable gene therapies have been priced near two million dollars. Still, the authors conclude that with optimized effector combinations, LNP-based hit-and-run delivery — already shown to sustain liver gene silencing for over a year in mice and over 90 days in non-human primates in PCSK9 studies — and clinically relevant models, precision epigenetic editing could deliver what nucleos(t)ide analogs never could: a stable, reversible, non-genotoxic functional cure for chronic hepatitis B.

Subject of Research: Epigenetic editing strategies to silence hepatitis B virus cccDNA and integrated DNA for a functional cure of chronic hepatitis B

Article Title: The promise of epigenetic editing strategies in functionally curing chronic hepatitis B virus infections

Article References: The promise of epigenetic editing strategies in functionally curing chronic hepatitis B virus infections. (n.d.). https://doi.org/10.1186/s43682-025-00041-3

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00041-3

Keywords: epigenetic editing, chronic hepatitis B, hepatitis B virus, cccDNA, integrated HBV DNA, dCas9, zinc-finger proteins, TALEs, KRAB, epidrugs, lipid nanoparticles, functional cure

The study began with a practical problem: researchers have lacked good tools to study the behavior of hepatitis B virus-specific T cells in a physiologically relevant setting. The team used a humanized mouse model carrying the human HLA-A11 molecule to identify a T cell receptor that recognizes HBc141-151, an epitope from the hepatitis B core antigen that is clinically relevant in human patients. This receptor, which the authors call HB-I, allowed them to generate transgenic mice whose entire CD8+ T cell population is specific for a single, human-relevant HBV epitope, providing a tractable platform for dissecting why these cells fail during chronic infection.

With that platform in hand, the researchers turned to an unbiased discovery strategy. Using a whole-genome CRISPR-Cas9 knockout library delivered into HBV-specific T cells, followed by screening under chronic antigen stimulation, they asked which genes, when deleted, would help T cells resist the dysfunctional state that normally develops. The screen converged on Ankrd11, a gene previously known as a chromatin regulator implicated in neural development and in Kabuki-like syndromes, but never before linked to T cell exhaustion. Loss of Ankrd11 consistently produced T cells that proliferated more vigorously and retained stronger effector characteristics.

The mechanistic picture that emerges from the paper is epigenetic. ANKRD11 appears to restrain the accessibility and acetylation of key effector genes. Using ATAC-seq, bulk RNA-seq and CUT&Tag profiling of the histone mark H3K27ac, the team showed that Ankrd11-deficient CD8+ T cells display increased chromatin openness and enhancer acetylation at loci encoding AP-1 family transcription factors, notably Fos and Fosb. Elevated AP-1 activity, in turn, drives a program of effector differentiation: the cells produce more granzyme B and interferon-gamma, resist the immunosuppressive conditions that normally silence them, and maintain function even when interleukin-2, a survival factor, is limiting.

Functionally, the consequences of losing this brake were striking. In mice carrying a replicating HBV plasmid or infected with recombinant HBV vectors, Ankrd11-deficient HBV-specific T cells expanded more robustly, infiltrated the liver more effectively, and drastically reduced serum levels of hepatitis B surface antigen, viral DNA and markers of liver damage. Parallel experiments using a second chronic infection model, lymphocytic choriomeningitis virus clone 13, confirmed the generality of the effect: adoptively transferred Ankrd11-deficient virus-specific P14 T cells showed enhanced granzyme expression, proliferation and viral control in the spleen and blood.

Perhaps the most conceptually interesting finding concerns the differentiation paths that exhausted T cells normally follow. In chronic infection and cancer, antigen-specific CD8+ T cells split into progenitor exhausted T cells, which express the transcription factor TCF-1 and serve as a self-renewing reservoir, and terminally exhausted T cells, which lose TCF-1 and are irreversibly dysfunctional. The authors found that Ankrd11 deficiency accelerates the conversion of progenitor exhausted cells into effector-like exhausted cells, but importantly, the resulting cells are cytotoxic and functional rather than inert. This suggests ANKRD11 does not simply maintain progenitor pools but actively gates how far exhausted cells differentiate toward effector competence.

The study also revealed a distinct route of reprogramming specific to chronic hepatitis B. A large fraction of HBV-specific CD8+ T cells in tolerant mice carries a PD-1-negative, TOX-negative phenotype that has resisted conventional checkpoint-based rescue strategies. When ANKRD11-mediated repression was relieved, these tolerant cells differentiated into PD-1-positive, KLRG1-positive effector cells armed with high granzyme levels, providing an explanation for the improved viral clearance. In other words, ANKRD11 deficiency unlocks an otherwise dormant pool of virus-specific cells that immune checkpoint blockade alone cannot reach.

The antitumor implications were tested directly in cancer models. Ankrd11-deficient CD8+ T cells promoted rejection of implanted tumors, enhanced intratumoral T cell activity, and acted synergistically with immune checkpoint blockade, potentiating the effect of PD-1 pathway inhibition. Given that the exhaustion of tumor-infiltrating lymphocytes is a central cause of immunotherapy failure, a single gene whose deletion reprograms effector differentiation under immunosuppressive conditions is an attractive candidate for therapeutic engineering, for example in chimeric antigen receptor or T cell receptor-engineered cell products. A provisional patent application has been filed based on the findings, underscoring the translational interest.

Caveats remain before ANKRD11 targeting reaches the clinic. ANKRD11 is a broad chromatin regulator with established roles in neural and cardiac development, so systemic inhibition is unlikely to be safe; the therapeutic window will probably lie in ex vivo engineering of T cells or in carefully targeted delivery. It will also be important to determine whether accelerated terminal differentiation comes at the cost of long-term memory formation. Nevertheless, the study delivers a clear conceptual advance: T cell dysfunction in chronic infection and cancer is not merely the product of inhibitory receptor signaling, but is epigenetically authored, and specific chromatin factors such as ANKRD11 can be removed to rewrite that script. For the hundreds of millions of people living with chronic hepatitis B, and for cancer patients whose T cells have gone quiet, that insight opens a new direction for immunotherapy design.

The concept of T cell exhaustion has shaped immunology for two decades. Since the landmark demonstration that chronically stimulated CD8+ T cells can regain function when inhibitory pathways are interrupted, researchers have catalogued a molecular signature of the dysfunctional state, and later work established the transcription factor TOX as a master architect of the exhaustion program, acting at both transcriptional and epigenetic levels. What has remained less clear is whether exhaustion is a fixed fate or a tunable state whose chromatin underpinnings can be deliberately rewritten. The new study adds weight to the second view by identifying a specific chromatin-associated protein whose removal shifts the balance of differentiation toward cytotoxic competence.

The methodological route to this finding is worth noting. Genome-wide CRISPR-Cas9 knockout screens have become a powerful way to uncover genes that constrain or enable T cell behavior, and previous efforts using this approach identified regulators such as REGNASE-1 and Roquin as suppressors of effector expansion and antitumor immunity. The present screen extends this logic into the setting of chronic hepatitis B virus infection, a context in which suppressive cues differ from those in tumors and in which conventional checkpoint blockade has shown only modest clinical benefit. That an unbiased screen converged on a gene with no prior immunological pedigree illustrates how phenotype-first discovery can bypass assumptions rooted in known pathways.

ANKRD11 itself carries an interesting dual history. It was first characterized as a chromatin regulator essential for neural development, and subsequent work showed it controls cardiac neural crest-mediated remodeling of the outflow tract. Its association with a Kabuki-like syndrome in humans reflects the pleiotropic consequences of disturbing a factor that operates broadly across tissues. This background both explains why the protein had escaped attention in immunology and reinforces the caution that any therapeutic interference must be confined to engineered cells rather than delivered systemically.

The AP-1 connection provides a mechanistic bridge to earlier T cell biology. AP-1 family transcription factors, built from Fos and Jun proteins, have long been recognized as immediate-early responders to T cell receptor signaling, and their activity is known to cooperate with other factors to specify effector genes. By showing that ANKRD11 restrains chromatin accessibility and H3K27 acetylation at AP-1 loci, the study suggests a route by which a chromatin regulator can gate a transcriptional program that is otherwise primed and waiting in naive and exhausted cells alike.

The authors have deposited the datasets underlying these conclusions in public repositories: bulk RNA-seq data under accession GSE299520, ATAC-seq data under GSE299519, and CUT&Tag data under GSE299521, with source data provided alongside the paper. No original code was generated. This transparency should allow groups working on T cell engineering to interrogate the chromatin changes directly and to test whether similar ANKRD11-sensitive programs operate in human tumor-infiltrating lymphocytes, a necessary step before the findings can inform next-generation cell therapy design.

Subject of Research: Epigenetic regulation of CD8+ T cell dysfunction in chronic viral infection and cancer

Article Title: ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer

Article References: Xu, W., Guo, J., Cao, X., Li, L., Xiao, P., Zhang, X., Jin, Q., Zhang, F., Hou, B., Li, M., & Zhou, X. (2026). ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer. Nature Immunology. https://doi.org/10.1038/s41590-026-02652-x

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02652-x

Keywords: ANKRD11, CD8+ T cells, T cell exhaustion, chronic hepatitis B, epigenetics, immunotherapy, CRISPR screen, AP-1 transcription factors, granzyme B, immune checkpoint blockade, tumor immunity, T cell receptor